Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicities
Mary-Ellen Taplin
Watch Prof. Mary-Ellen Taplin provide a commentary on the benefits/risk profile of life-prolonging therapies in patients with mHSPC and some practical considerations to be taken into account while treating such patients. Click on the Chapters icon in the video toolbar to navigate through the sections of the video
